Affimed (AFMD) Stock Forecast, Price Target & Predictions
AFMD Stock Forecast
Affimed stock forecast is as follows: an average price target of $7.50 (represents a 87.50% upside from AFMD’s last price of $4.00) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
AFMD Price Target
The average price target for Affimed (AFMD) is $7.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $5.00. This represents a potential 87.50% upside from AFMD's last price of $4.00.
AFMD Analyst Ratings
According to 5 Wall Street analysts, Affimed's rating consensus is 'Buy'. The analyst rating breakdown for AFMD stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Affimed Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 01, 2024 | Bradley Canino | Stifel Nicolaus | $5.00 | $5.30 | -5.66% | 25.00% |
| Apr 01, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $10.00 | $5.30 | 88.68% | 150.00% |
The latest Affimed stock forecast, released on Apr 01, 2024 by Bradley Canino from Stifel Nicolaus, set a price target of $5.00, which represents a -5.66% decrease from the stock price at the time of the forecast ($5.30), and a 25.00% increase from AFMD last price ($4.00).
Affimed Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $7.50 |
| Last Closing Price | $4.00 | $4.00 | $4.00 |
| Upside/Downside | -100.00% | -100.00% | 87.50% |
In the current month, the average price target of Affimed stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Affimed's last price of $4.00. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 12, 2024 | Laidlaw | Buy | Buy | Hold |
| Apr 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 12, 2022 | H.C. Wainwright | - | Buy | Initialise |
| Oct 11, 2022 | Stifel Nicolaus | - | Positive | Downgrade |
| Mar 31, 2022 | Piper Sandler | - | Overweight | Initialise |
| Feb 23, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
Affimed's last stock rating was published by Laidlaw on Jun 12, 2024. The company gave AFMD a "Buy" rating, the same as its previous rate.
Affimed Financial Forecast
Affimed Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.51M | $11.16M | $14.89M | $7.30M | $8.01M | $10.34M | $8.66M | $9.71M | $11.66M | $9.75M | $10.54M | $2.93M | $5.13M | $3.93M | $2.10M |
| Avg Forecast | $151.48K | $151.73K | $151.98K | $152.23K | $369.09K | $369.09K | $369.09K | $369.09K | $1.91M | $1.58M | $1.16M | $458.57K | $1.66M | $1.93M | $4.65M | $6.16M | $6.92M | $6.29M | $8.83M | $10.31M | $8.98M | $9.59M | $9.01M | $10.63M | $16.63M | $8.79M | $5.20M | $5.47M | $3.09M | $3.71M |
| High Forecast | $151.48K | $151.73K | $151.98K | $152.23K | $369.09K | $369.09K | $369.09K | $369.09K | $1.91M | $2.52M | $1.16M | $458.57K | $2.62M | $1.93M | $4.65M | $6.16M | $6.92M | $6.29M | $8.83M | $10.31M | $8.98M | $9.59M | $9.01M | $10.63M | $16.63M | $8.79M | $5.20M | $5.47M | $3.09M | $3.71M |
| Low Forecast | $151.48K | $151.73K | $151.98K | $152.23K | $369.09K | $369.09K | $369.09K | $369.09K | $1.91M | $626.62K | $1.16M | $458.57K | $643.08K | $1.93M | $4.65M | $6.16M | $6.92M | $6.29M | $8.83M | $10.31M | $8.98M | $9.59M | $9.01M | $10.63M | $16.63M | $8.79M | $5.20M | $5.47M | $3.09M | $3.71M |
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 2 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 1.61% | 2.37% | 0.83% | 0.78% | 1.15% | 0.90% | 1.08% | 1.10% | 0.59% | 1.20% | 0.56% | 0.94% | 1.27% | 0.57% |
Affimed's average Quarter revenue forecast for Jun 23 based on 2 analysts is $4.65M, with a low forecast of $4.65M, and a high forecast of $4.65M. AFMD's average Quarter revenue forecast represents a 3.18% increase compared to the company's last Quarter revenue of $4.51M (Mar 23).
Affimed EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 2 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-30.66M | $-27.85M | $-18.73M | $-21.33M | $-16.85M | $-22.51M | $-16.56M | $-18.24M | $1.83M | $-14.66M | $-5.65M | $-11.90M | $-7.95M | $-12.64M | $-10.55M |
| Avg Forecast | $-151.48K | $-151.73K | $-151.98K | $-152.23K | $-369.09K | $-369.09K | $-369.09K | $-369.09K | $-1.91M | $-1.58M | $-1.16M | $-458.57K | $-1.66M | $-1.93M | $-4.65M | $-6.16M | $-6.92M | $-6.29M | $-8.83M | $-9.88M | $-8.61M | $-11.47M | $-34.88M | $3.71M | $-15.95M | $-6.36M | $-9.16M | $-7.95M | $-2.96M | $-9.89M |
| High Forecast | $-151.48K | $-151.73K | $-151.98K | $-152.23K | $-369.09K | $-369.09K | $-369.09K | $-369.09K | $-1.91M | $-626.62K | $-1.16M | $-458.57K | $-643.08K | $-1.93M | $-4.65M | $-6.16M | $-6.92M | $-6.29M | $-8.83M | $-9.88M | $-8.61M | $-9.17M | $-27.90M | $4.45M | $-15.95M | $-5.09M | $-7.32M | $-6.36M | $-2.96M | $-7.91M |
| Low Forecast | $-151.48K | $-151.73K | $-151.98K | $-152.23K | $-369.09K | $-369.09K | $-369.09K | $-369.09K | $-1.91M | $-2.52M | $-1.16M | $-458.57K | $-2.62M | $-1.93M | $-4.65M | $-6.16M | $-6.92M | $-6.29M | $-8.83M | $-9.88M | $-8.61M | $-13.76M | $-41.86M | $2.96M | $-15.95M | $-7.63M | $-10.99M | $-9.53M | $-2.96M | $-11.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.97% | 4.03% | 2.98% | 2.42% | 1.70% | 2.61% | 1.44% | 0.52% | 0.49% | 0.92% | 0.89% | 1.30% | 1.00% | 4.27% | 1.07% |
3 analysts predict AFMD's average Quarter EBITDA for Jun 21 to be $-34.88M, with a high of $-27.90M and a low of $-41.86M. This is -2006.02% lower than Affimed's previous annual EBITDA (Mar 21) of $1.83M.
Affimed Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 2 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-31.98M | $-36.73M | $-13.77M | $-17.16M | $-16.66M | $-23.27M | $-17.09M | $-18.75M | $1.41M | $-14.87M | $-5.97M | $-12.24M | $-8.29M | $-12.99M | $-10.88M |
| Avg Forecast | $-14.83M | $-14.87M | $-12.92M | $-12.95M | $-11.24M | $-9.61M | $-8.28M | $-8.86M | $-10.00M | $-13.46M | $-14.80M | $-23.76M | $-23.64M | $-28.26M | $-28.60M | $-29.22M | $-29.11M | $-26.55M | $-25.29M | $-263.02M | $-239.26M | $-11.84M | $-35.86M | $2.86M | $-22.20M | $-6.71M | $-9.41M | $-8.29M | $-266.69M | $-10.20M |
| High Forecast | $-14.83M | $-14.87M | $-12.92M | $-12.95M | $-11.24M | $-9.61M | $-8.28M | $-8.86M | $-10.00M | $-3.51M | $-14.80M | $-23.76M | $-17.84M | $-28.26M | $-28.60M | $-29.22M | $-29.11M | $-26.55M | $-25.29M | $-263.02M | $-239.26M | $-9.47M | $-28.69M | $3.43M | $-22.20M | $-5.37M | $-7.53M | $-6.63M | $-266.69M | $-8.16M |
| Low Forecast | $-14.83M | $-14.87M | $-12.92M | $-12.95M | $-11.24M | $-9.61M | $-8.28M | $-8.86M | $-10.00M | $-17.55M | $-14.80M | $-23.76M | $-30.63M | $-28.26M | $-28.60M | $-29.22M | $-29.11M | $-26.55M | $-25.29M | $-263.02M | $-239.26M | $-14.20M | $-43.04M | $2.29M | $-22.20M | $-8.05M | $-11.30M | $-9.95M | $-266.69M | $-12.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 1.26% | 0.52% | 0.68% | 0.06% | 0.10% | 1.44% | 0.52% | 0.49% | 0.67% | 0.89% | 1.30% | 1.00% | 0.05% | 1.07% |
Affimed's average Quarter net income forecast for Jun 21 is $-35.86M, with a range of $-43.04M to $-28.69M. AFMD's average Quarter net income forecast represents a -2639.89% decrease compared to the company's last Quarter net income of $1.41M (Mar 21).
Affimed SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 2 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.85M | $8.57M | $8.09M | $8.37M | $7.04M | $7.45M | $6.84M | $5.44M | $4.49M | $4.13M | $3.46M | $2.61M | $3.52M | $2.70M | $2.79M |
| Avg Forecast | $161.20K | $161.47K | $161.74K | $162.00K | $392.78K | $392.78K | $392.78K | $392.78K | $2.04M | $1.68M | $1.23M | $488.01K | $1.76M | $2.05M | $4.95M | $6.56M | $7.36M | $6.70M | $9.39M | $5.66M | $4.93M | $4.74M | $4.95M | $9.08M | $9.13M | $3.89M | $2.00M | $3.52M | $1.70M | $2.62M |
| High Forecast | $161.20K | $161.47K | $161.74K | $162.00K | $392.78K | $392.78K | $392.78K | $392.78K | $2.04M | $2.68M | $1.23M | $488.01K | $2.79M | $2.05M | $4.95M | $6.56M | $7.36M | $6.70M | $9.39M | $5.66M | $4.93M | $5.68M | $4.95M | $10.90M | $9.13M | $4.66M | $2.41M | $4.23M | $1.70M | $3.14M |
| Low Forecast | $161.20K | $161.47K | $161.74K | $162.00K | $392.78K | $392.78K | $392.78K | $392.78K | $2.04M | $666.85K | $1.23M | $488.01K | $684.36K | $2.05M | $4.95M | $6.56M | $7.36M | $6.70M | $9.39M | $5.66M | $4.93M | $3.79M | $4.95M | $7.27M | $9.13M | $3.11M | $1.60M | $2.82M | $1.70M | $2.09M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.16% | 1.21% | 0.89% | 1.25% | 1.51% | 1.44% | 1.10% | 0.49% | 0.45% | 0.89% | 1.30% | 1.00% | 1.59% | 1.07% |
Affimed's average Quarter SG&A projection for Jun 23 is $4.95M, based on 2 Wall Street analysts, with a range of $4.95M to $4.95M. The forecast indicates a -27.71% fall compared to AFMD last annual SG&A of $6.85M (Mar 23).
Affimed EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 2 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.21 | $-0.26 | $-0.09 | $-0.12 | $-0.14 | $-0.29 | $-0.14 | $-0.16 | $0.01 | $-0.13 | $-0.07 | $-0.16 | $-0.11 | $-0.17 | $-0.17 |
| Avg Forecast | $-0.97 | $-0.97 | $-0.84 | $-0.85 | $-0.73 | $-0.63 | $-0.54 | $-0.58 | $-0.65 | $-0.88 | $-0.97 | $-1.55 | $-1.55 | $-1.85 | $-1.87 | $-1.91 | $-1.90 | $-1.74 | $-1.67 | $-1.76 | $-1.60 | $-1.40 | $-0.86 | $-1.00 | $-0.15 | $-0.82 | $-1.32 | $-1.29 | $-1.79 | $-1.79 |
| High Forecast | $-0.97 | $-0.97 | $-0.84 | $-0.85 | $-0.73 | $-0.63 | $-0.54 | $-0.58 | $-0.65 | $-0.23 | $-0.97 | $-1.55 | $-1.17 | $-1.85 | $-1.87 | $-1.91 | $-1.90 | $-1.74 | $-1.67 | $-1.76 | $-1.60 | $-1.40 | $-0.86 | $-1.00 | $-0.15 | $-0.82 | $-1.32 | $-1.29 | $-1.79 | $-1.79 |
| Low Forecast | $-0.97 | $-0.97 | $-0.84 | $-0.85 | $-0.73 | $-0.63 | $-0.54 | $-0.58 | $-0.65 | $-1.15 | $-0.97 | $-1.55 | $-2.00 | $-1.85 | $-1.87 | $-1.91 | $-1.90 | $-1.74 | $-1.67 | $-1.76 | $-1.60 | $-1.40 | $-0.86 | $-1.00 | $-0.15 | $-0.82 | $-1.32 | $-1.29 | $-1.79 | $-1.79 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.11% | 0.14% | 0.05% | 0.07% | 0.08% | 0.18% | 0.10% | 0.19% | -0.01% | 0.86% | 0.09% | 0.12% | 0.09% | 0.10% | 0.09% |
According to 3 Wall Street analysts, Affimed's projected average Quarter EPS for Jun 21 is $-0.86, with a low estimate of $-0.86 and a high estimate of $-0.86. This represents a -8665.40% decrease compared to AFMD previous annual EPS of $0.01 (Mar 21).
Affimed Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| ADCT | ADC Therapeutics SA | $3.10 | $9.33 | 200.97% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ADAP | Adaptimmune Therapeutics | $1.11 | $2.83 | 154.95% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| LPTX | Leap Therapeutics | $2.74 | $5.50 | 100.73% | Buy |
| AFMD | Affimed | $4.00 | $7.50 | 87.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| CRVS | Corvus Pharmaceuticals | $5.10 | $7.00 | 37.25% | Buy |
| AGEN | Agenus | $6.26 | $8.00 | 27.80% | Hold |
AFMD Forecast FAQ
Is Affimed a good buy?
Yes, according to 5 Wall Street analysts, Affimed (AFMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of AFMD's total ratings.
What is AFMD's price target?
Affimed (AFMD) average price target is $7.5 with a range of $5 to $10, implying a 87.50% from its last price of $4. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Affimed stock go up soon?
According to Wall Street analysts' prediction for AFMD stock, the company can go up by 87.50% (from the last price of $4 to the average price target of $7.5), up by 150.00% based on the highest stock price target, and up by 25.00% based on the lowest stock price target.
Can Affimed stock reach $6?
AFMD's average twelve months analyst stock price target of $7.5 supports the claim that Affimed can reach $6 in the near future.
What are Affimed's analysts' financial forecasts?
Affimed's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.48M (high $1.48M, low $1.48M), average EBITDA is $-1.476M (high $-1.476M, low $-1.476M), average net income is $-37.991M (high $-37.991M, low $-37.991M), average SG&A $1.57M (high $1.57M, low $1.57M), and average EPS is $-2.483 (high $-2.483, low $-2.483). AFMD's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $607.42K (high $607.42K, low $607.42K), average EBITDA is $-607K (high $-607K, low $-607K), average net income is $-55.565M (high $-55.565M, low $-55.565M), average SG&A $646.41K (high $646.41K, low $646.41K), and average EPS is $-3.631 (high $-3.631, low $-3.631).
Did the AFMD's actual financial results beat the analysts' financial forecasts?
Based on Affimed's last annual report (Dec 2022), the company's revenue was $41.35M, beating the average analysts forecast of $32.35M by 27.84%. Apple's EBITDA was $-86.637M, beating the average prediction of $-31.925M by 171.38%. The company's net income was $-86.004M, missing the average estimation of $-344M by -75.00%. Apple's SG&A was $32.08M, beating the average forecast of $29.11M by 10.17%. Lastly, the company's EPS was $-0.6, missing the average prediction of $-7.07 by -91.51%. In terms of the last quarterly report (Mar 2023), Affimed's revenue was $4.51M, missing the average analysts' forecast of $6.16M by -26.82%. The company's EBITDA was $-30.662M, beating the average prediction of $-6.163M by 397.50%. Affimed's net income was $-31.983M, beating the average estimation of $-29.218M by 9.46%. The company's SG&A was $6.85M, beating the average forecast of $6.56M by 4.44%. Lastly, the company's EPS was $-0.21, missing the average prediction of $-1.91 by -89.00%